注射用缓释纳曲酮治疗晚期酒精相关性肝病合并酒精使用障碍的安全性与耐受性
该回顾性病例系列纳入14例晚期酒精相关性肝病(ALD)成人患者,接受至少一剂缓释纳曲酮(XR-NTX)380 mg肌内注射,中位随访127天。4例(29%)出现轻度不良事件,无肝毒性或肝功能失代偿,8例(57%)饮酒量减少,磷脂酰乙醇(PEth)水平呈非显著下降。
要点
- 14例晚期ALD患者接受XR-NTX 380 mg肌内注射,中位随访127天,无肝毒性或肝功能失代偿。
- 4例(29%)出现轻度不良事件,包括注射部位疼痛、恶心呕吐、疲劳和性方面副作用。
- 8例(57%)饮酒量减少,PEth水平呈非显著下降。
核心结论
- 在该病例系列中,XR-NTX在晚期ALD患者中耐受良好,无肝毒性或肝功能失代偿的证据。
研究设计与样本
- 回顾性病例系列,纳入2023年至2025年3月期间在一家三级医疗中心接受至少一剂XR-NTX 380 mg肌内注射的成人ALD患者,从电子健康记录提取临床数据和实验室检查,最短随访12周。
主要发现
- 共纳入14例ALD患者,其中2例为F3纤维化,9例为Child A-B级肝硬化;中位年龄51[44-65]岁,64%为男性,中位随访127天。
- 4例患者(29%)出现轻度不良事件(注射部位疼痛、恶心呕吐、疲劳和性方面副作用),无肝毒性或肝功能失代偿。
- 随访期间肝功能检查及MELD/Child-Pugh评分无显著变化。
- 8例参与者(57%)饮酒量减少,PEth水平呈非显著下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacologic treatment of alcohol use disorder (AUD) in patients with advanced alcohol-associated liver disease (ALD) remains underutilised due to concerns regarding hepatotoxicity. Injectable extended-release naltrexone (XR-NTX) may offer a safer alternative by avoiding first-pass hepatic metabolism, but data on its safety and effectiveness in patients with advanced ALD are limited. AIM: To describe the clinical experience with XR-NTX in individuals with advanced ALD, evaluating its safety, tolerability and impact on liver function and alcohol use. METHODS: Retrospective case series of adults with ALD who received at least one dose of XR-NTX 380 mg IM at a tertiary care centre between 2023 and March 2025. Clinical data and laboratory tests were extracted from electronic health records over a minimum follow-up of 12 weeks. Safety was assessed based on adverse events and liver biochemistry. Alcohol use was evaluated using phosphatidylethanol (PEth) levels. RESULTS: Fourteen individuals with ALD were included (2 had F3 and 9 cirrhosis Child A-B). The median age was 51 [44-65] years, 64% were male, and median follow-up was 127 days. Four patients (29%) experienced mild adverse effects (injection site pain, nausea and vomiting, fatigue and sexual side effects); none had hepatotoxicity or hepatic decompensation. No significant changes in liver function tests or MELD/Child-Pugh scores were observed during the follow-up period. Eight participants (57%) had a decrease in alcohol consumption, with a non-significant decline in PEth levels. CONCLUSION: In this case series, XR-NTX was well tolerated in patients with advanced ALD, without evidence of hepatotoxicity or liver decompensation.
引用
- Díaz LA, Collier S, Yin J, et al. Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease. Aliment Pharmacol Ther. 2025. PMID: 40515940. doi:10.1111/apt.70237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。